{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["16(19)"],"submitter":["Heini AD"],"pubmed_abstract":["<h4>Introduction</h4>The growing body of evidence around sexual and gender dimorphism in medicine, particularly in oncology, has highlighted differences in treatment response, outcomes, and side effects between males and females. Differences in drug metabolism, distribution, and elimination, influenced by factors like body composition and enzyme expression, contribute to these variations.<h4>Methods</h4>We retrospectively analyzed data of 112 multiple myeloma (MM) patients treated with first-line high-dose chemotherapy (HDCT) with treosulfan and melphalan (TreoMel) followed by autologous stem cell transplantation (ASCT) at a single academic center between January 2020 and August 2022. We assessed response rate, progression-free survival (PFS), overall survival (OS), and toxicities in relat"],"journal":["Cancers"],"pagination":["3364"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11475554"],"repository":["biostudies-literature"],"pubmed_title":["Gender-Specific Prognostic Impact of Treosulfan Levels in High-Dose Chemotherapy for Multiple Myeloma."],"pmcid":["PMC11475554"],"pubmed_authors":["Kammermann K","Largiader CR","Bacher U","Jeker B","Pabst T","Heini AD","Hayoz M","Aebi Y","Nilius H"],"additional_accession":[]},"is_claimable":false,"name":"Gender-Specific Prognostic Impact of Treosulfan Levels in High-Dose Chemotherapy for Multiple Myeloma.","description":"<h4>Introduction</h4>The growing body of evidence around sexual and gender dimorphism in medicine, particularly in oncology, has highlighted differences in treatment response, outcomes, and side effects between males and females. Differences in drug metabolism, distribution, and elimination, influenced by factors like body composition and enzyme expression, contribute to these variations.<h4>Methods</h4>We retrospectively analyzed data of 112 multiple myeloma (MM) patients treated with first-line high-dose chemotherapy (HDCT) with treosulfan and melphalan (TreoMel) followed by autologous stem cell transplantation (ASCT) at a single academic center between January 2020 and August 2022. We assessed response rate, progression-free survival (PFS), overall survival (OS), and toxicities in relat","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Oct","modification":"2026-07-05T03:17:48.423Z","creation":"2025-04-04T23:50:44.434Z"},"accession":"S-EPMC11475554","cross_references":{"pubmed":["39409984"],"doi":["10.3390/cancers16193364"]}}